Mercer Global Advisors
CLDI icon

Mercer Global Advisors’s Calidi Biotherapeutics CLDI Stock Holding History

Mercer Global Advisors’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9 Buy
+3
New +$10 ﹤0.01% 6062

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Mercer Global Advisors's CLDI Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Calidi Biotherapeutics (CLDI) in Q2 2026: 3 shares worth $9. The stake represents ﹤0.01% of the portfolio and ranks #6062 among its holdings.

14 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Mercer Global Advisors held 3 shares of Calidi Biotherapeutics worth $9 as of Q2 2026.
  • Calidi Biotherapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #6062 holding.
  • 14 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.